➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Medtronic
McKinsey
AstraZeneca
Express Scripts

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

BREVIBLOC Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Brevibloc patents expire, and what generic alternatives are available?

Brevibloc is a drug marketed by Baxter Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in twenty-five countries.

The generic ingredient in BREVIBLOC is esmolol hydrochloride. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Brevibloc

A generic version of BREVIBLOC was approved as esmolol hydrochloride by WEST-WARD PHARMS INT on August 10th, 2004.

  Get Started Free

Drug patent expirations by year for BREVIBLOC
Drug Prices for BREVIBLOC

See drug prices for BREVIBLOC

Recent Clinical Trials for BREVIBLOC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zagazig UniversityPhase 2
Cristália Produtos Químicos Farmacêuticos Ltda.Phase 4
University Hospital Bispebjerg and FrederiksbergPhase 4

See all BREVIBLOC clinical trials

Pharmacology for BREVIBLOC
Paragraph IV (Patent) Challenges for BREVIBLOC
Tradename Dosage Ingredient NDA Submissiondate
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER INJECTABLE;INJECTION esmolol hydrochloride 019386 2014-01-31
BREVIBLOC IN PLASTIC CONTAINER INJECTABLE;INJECTION esmolol hydrochloride 019386 2014-01-31
BREVIBLOC INJECTABLE;INJECTION esmolol hydrochloride 019386 2014-01-31

US Patents and Regulatory Information for BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988 DISCN No No   Get Started Free   Get Started Free   Get Started Free
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 DISCN No No   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988   Get Started Free   Get Started Free
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003   Get Started Free   Get Started Free
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Colorcon
Merck
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.